CN111757742B - 含有地夸磷索及阳离子性聚合物的眼科用组合物 - Google Patents

含有地夸磷索及阳离子性聚合物的眼科用组合物 Download PDF

Info

Publication number
CN111757742B
CN111757742B CN201980015357.8A CN201980015357A CN111757742B CN 111757742 B CN111757742 B CN 111757742B CN 201980015357 A CN201980015357 A CN 201980015357A CN 111757742 B CN111757742 B CN 111757742B
Authority
CN
China
Prior art keywords
cationic
eye
diquafosol
copolymers
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980015357.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111757742A (zh
Inventor
高桥恭平
浅田博之
神村明日香
森岛健司
桃川雄介
远藤健一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to CN202311151214.4A priority Critical patent/CN117137866A/zh
Publication of CN111757742A publication Critical patent/CN111757742A/zh
Application granted granted Critical
Publication of CN111757742B publication Critical patent/CN111757742B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201980015357.8A 2018-02-28 2019-02-27 含有地夸磷索及阳离子性聚合物的眼科用组合物 Active CN111757742B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311151214.4A CN117137866A (zh) 2018-02-28 2019-02-27 含有地夸磷索及阳离子性聚合物的眼科用组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
JP2018-035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311151214.4A Division CN117137866A (zh) 2018-02-28 2019-02-27 含有地夸磷索及阳离子性聚合物的眼科用组合物

Publications (2)

Publication Number Publication Date
CN111757742A CN111757742A (zh) 2020-10-09
CN111757742B true CN111757742B (zh) 2023-09-26

Family

ID=67806273

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980015357.8A Active CN111757742B (zh) 2018-02-28 2019-02-27 含有地夸磷索及阳离子性聚合物的眼科用组合物
CN202311151214.4A Pending CN117137866A (zh) 2018-02-28 2019-02-27 含有地夸磷索及阳离子性聚合物的眼科用组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311151214.4A Pending CN117137866A (zh) 2018-02-28 2019-02-27 含有地夸磷索及阳离子性聚合物的眼科用组合物

Country Status (14)

Country Link
US (1) US20210000844A1 (https=)
EP (1) EP3760207A4 (https=)
JP (5) JP6716800B2 (https=)
KR (3) KR20250053220A (https=)
CN (2) CN111757742B (https=)
BR (1) BR112020017661A2 (https=)
CA (1) CA3091700A1 (https=)
EA (1) EA202092030A1 (https=)
MX (2) MX2020008925A (https=)
PH (1) PH12020551313B1 (https=)
SG (1) SG11202007977RA (https=)
TW (4) TW202600146A (https=)
UA (1) UA129517C2 (https=)
WO (1) WO2019168023A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12020551313B1 (en) * 2018-02-28 2024-02-28 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
EP4393510A4 (en) * 2021-09-30 2025-08-06 Rohto Pharma OPHTHALMOLOGICAL COMPOSITION
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088758A2 (en) * 2005-02-14 2006-08-24 Johnson & Johnson Vision Care, Inc. A comfortable ophthalmic device and methods of its production
CN104203254A (zh) * 2012-03-26 2014-12-10 参天制药株式会社 含有地夸磷索的滴眼液
CN106456536A (zh) * 2014-05-07 2017-02-22 克罗马药品股份有限公司 水性眼用溶液和治疗干眼综合征的方法
CN106456791A (zh) * 2014-06-10 2017-02-22 日本乐敦制药株式会社 眼科用水性组合物
CN107582605A (zh) * 2016-07-07 2018-01-16 萨尔瓦特实验室股份有限公司 眼用组合物
JP2018028673A (ja) * 2017-10-03 2018-02-22 株式会社メニコン 眼科用組成液及びその使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
KR20010013797A (ko) 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
BR0111297A (pt) * 2000-05-30 2004-01-06 Santen Pharmaceutical Co Ltd Promotor de migração epitelial corneana
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
CA2717825A1 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd. Opthalmic composition
MX2013007502A (es) * 2010-12-28 2013-08-01 Santen Pharmaceutical Co Ltd Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
TWI709405B (zh) * 2014-12-25 2020-11-11 日商參天製藥股份有限公司 水性點眼液及其應用
KR101587385B1 (ko) 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
WO2017033967A1 (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
MY196323A (en) * 2017-04-25 2023-03-24 Wakamoto Pharma Co Ltd Thermo-Responsive Gelling Artificial Lacrima
PH12020551313B1 (en) * 2018-02-28 2024-02-28 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088758A2 (en) * 2005-02-14 2006-08-24 Johnson & Johnson Vision Care, Inc. A comfortable ophthalmic device and methods of its production
CN104203254A (zh) * 2012-03-26 2014-12-10 参天制药株式会社 含有地夸磷索的滴眼液
CN106456536A (zh) * 2014-05-07 2017-02-22 克罗马药品股份有限公司 水性眼用溶液和治疗干眼综合征的方法
CN106456791A (zh) * 2014-06-10 2017-02-22 日本乐敦制药株式会社 眼科用水性组合物
CN107582605A (zh) * 2016-07-07 2018-01-16 萨尔瓦特实验室股份有限公司 眼用组合物
JP2018028673A (ja) * 2017-10-03 2018-02-22 株式会社メニコン 眼科用組成液及びその使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes;Shizuka Koh;《Clin Ophthalmol》;第9卷;全文 *
Combining Sodium Hyaluronate and Polyvinylpyrrolidone Therapies for the Rabbit Cornea: A New Approach to Relief of the Human Dry Eye Syndrome;Moshe Ehrenberg et al.;《Current Eye Research》;20141020;第40卷(第9期);第4页最后一段 *
双氯芬酸钠滴眼液刺激性的缓解;孙刚等;《药学研究》;第32卷(第1期);全文 *
干眼的药物治疗现状及进展;边德换等;《当代医学》;20090825(第24期);全文 *
段辉.药物载体.《眼科临床药物手册》.辽宁科学出版社,2007,第2页. *

Also Published As

Publication number Publication date
JP2020138980A (ja) 2020-09-03
KR20250053220A (ko) 2025-04-21
TW202600146A (zh) 2026-01-01
JP7297718B2 (ja) 2023-06-26
TW202423451A (zh) 2024-06-16
CN117137866A (zh) 2023-12-01
TW202306572A (zh) 2023-02-16
EA202092030A1 (ru) 2020-11-16
KR20200127002A (ko) 2020-11-09
US20210000844A1 (en) 2021-01-07
KR102796051B1 (ko) 2025-04-14
MX2020008925A (es) 2020-10-01
CA3091700A1 (en) 2019-09-06
JP2026034664A (ja) 2026-02-27
JP2022136152A (ja) 2022-09-15
TWI898399B (zh) 2025-09-21
EP3760207A1 (en) 2021-01-06
CN111757742A (zh) 2020-10-09
SG11202007977RA (en) 2020-09-29
JPWO2019168023A1 (ja) 2020-05-28
WO2019168023A1 (ja) 2019-09-06
TW202000212A (zh) 2020-01-01
JP2024045506A (ja) 2024-04-02
TWI781296B (zh) 2022-10-21
BR112020017661A2 (pt) 2020-12-22
EP3760207A4 (en) 2023-10-04
JP7472202B2 (ja) 2024-04-22
TWI833406B (zh) 2024-02-21
JP6716800B2 (ja) 2020-07-01
UA129517C2 (uk) 2025-05-21
JP7796782B2 (ja) 2026-01-09
MX2022014791A (es) 2023-01-16
PH12020551313A1 (en) 2021-09-06
KR20220163519A (ko) 2022-12-09
PH12020551313B1 (en) 2024-02-28
KR102472773B1 (ko) 2022-11-30

Similar Documents

Publication Publication Date Title
CN111757742B (zh) 含有地夸磷索及阳离子性聚合物的眼科用组合物
CN113518646B (zh) 含有地夸磷索或其盐，乙烯基系高分子及纤维素系高分子的眼科用组合物
CN114286670B (zh) 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
HK40037570A (en) Ophthalmic composition comprising diquafosol and cationic polymer
HK40037570B (zh) 含有地夸磷索及阳离子性聚合物的眼科用组合物
JP2026069626A (ja) ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
HK40035045A (en) Ophthalmic composition comprising diquafosol and cationic polymer
EA044372B1 (ru) Офтальмологическая композиция, включающая диквафозол и катионный полимер

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037570

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant